drugset

drugset / Trial / NCT01289743

Etanercept (Enbrel) in Ankylosing Spondylitis

NCT01289743 ↗

Phase 2 Unknown 24 enrolled Charite University, Berlin, Germany Rheumazentrum Ruhrgebiet · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study has the aim to investigate the efficacy and safety of etanercept in patients with active ankylosing spondylitis (AS) over 520 weeks.

Timeline

Start: 2002-02
Primary completion: 2003-09
Completion: 2012-05

Publications

Baraliakos X, Haibel H, Fritz C, Listing J, Heldmann F, Braun J, Sieper J. Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years. Arthritis Res Ther. 2013;15(3):R67. doi: 10.1186/ar4244.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etanercept	Protein / enzyme biologic	25 mg	Subcutaneous

Indications